Display options
Cite
Chitty LS, Hudgins L, Norton ME. Current controversies in prenatal diagnosis 2: Cell-free DNA prenatal screening should be used to identify all chromosome abnormalities. Prenat Diagn. 2018;38(3):160-165doi: 10.1002/pd.5216.
Chitty, L. S., Hudgins, L., & Norton, M. E. (2018). Current controversies in prenatal diagnosis 2: Cell-free DNA prenatal screening should be used to identify all chromosome abnormalities. Prenatal diagnosis, 38(3), 160-165. https://doi.org/10.1002/pd.5216
Chitty, Lyn S, et al. "Current controversies in prenatal diagnosis 2: Cell-free DNA prenatal screening should be used to identify all chromosome abnormalities." Prenatal diagnosis vol. 38,3 (2018): 160-165. doi: https://doi.org/10.1002/pd.5216
Chitty LS, Hudgins L, Norton ME. Current controversies in prenatal diagnosis 2: Cell-free DNA prenatal screening should be used to identify all chromosome abnormalities. Prenat Diagn. 2018 Feb;38(3):160-165. doi: 10.1002/pd.5216. PMID: 29417608.
Copy Download .nbib Format: NLM
Share it on

Prenat Diagn. 2018 Feb;38(3):160-165. doi: 10.1002/pd.5216.

Current controversies in prenatal diagnosis 2: Cell-free DNA prenatal screening should be used to identify all chromosome abnormalities.

Prenatal diagnosis

Lyn S Chitty, Louanne Hudgins, Mary E Norton

Affiliations

  1. UCL Great Ormond Street Institute of Child Health, Great Ormond Street NHS Foundation Trust, London, UK.
  2. Pediatrics/Medical Genetics, Stanford University, Stanford, CA, USA.
  3. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA.

PMID: 29417608 DOI: 10.1002/pd.5216

Abstract

Noninvasive prenatal testing (NIPT) using cell-free DNA (cfDNA) from maternal serum has been clinically available since 2011. This technology has revolutionized our ability to screen for the common aneuploidies trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. More recently, clinical laboratories have offered screening for other chromosome abnormalities including sex chromosome abnormalities and copy number variants (CNV) without little published data on the sensitivity, specificity, and positive predictive value. In this debate, the pros and cons of performing prenatal screening via cfDNA for all chromosome abnormalities is discussed. At the time of the debate in 2017, the general consensus was that the literature does not yet support using this technology to screen for all chromosome abnormalities and that education is key for both providers and the patients so that the decision-making process is as informed as possible.

© 2018 John Wiley & Sons, Ltd.

Substances

MeSH terms

Publication Types

Grant support